Welcome to our dedicated page for Kraig Biocraft Laboratories In news (Ticker: KBLB), a resource for investors and traders seeking the latest updates and insights on Kraig Biocraft Laboratories In stock.
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) regularly issues detailed news releases about its work in recombinant spider silk and bioengineered fibers. The company describes itself as a world leader in spider silk technology and uses its news flow to report on production milestones, facility expansions, scientific progress, and commercial engagements.
News items often highlight advances in the company’s BAM-1 and BAM-1 Alpha hybrid silkworm lines, including selective breeding achievements that increase cocoon shell weight, throughput, and production efficiency. Kraig Biocraft Laboratories also reports on the launch and completion of spider silk production cycles, the deployment of BAM-1 Alpha as its primary production hybrid, and the integration of diapause egg management into its rearing operations.
Another recurring theme in KBLB news is the build-out of production infrastructure in Southeast Asia. Releases cover topics such as taking possession of additional silkworm rearing centers, relocating facilities to protected highlands, and maintaining multiple, parallel production sites to support scalability and resilience. The company also reports on securing usage rights to government-owned mulberry gardens and taking control of mulberry fields dedicated to its operations, emphasizing feedstock security and vertical coordination.
Investors and observers can also find updates on commercial and research developments, including pilot programs with a globally recognized performance sports apparel brand and announcements about scientific leadership and breakthroughs in advanced fibers and bioengineered materials. Together, these news items provide an ongoing view into Kraig Biocraft Laboratories’ efforts to expand spider silk production capacity, refine its technology, and pursue high-value applications in performance textiles, technical apparel, and other markets.
Kraig Biocraft Laboratories (OTCQB: KBLB) began processing nearly 1.8 metric tons of recombinant spider silk cocoons into finished reeled silk, a production record after exceeding 1.3 metric tons in March.
The reeling is underway with a production partner and is expected to finish by month-end, creating the company's largest-ever inventory for luxury, performance textile, and industrial uses.
Summary not available.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced senior management is traveling to South East Asia following a record monthly production of 1.3 metric tons of recombinant spider silk cocoons on April 13, 2026. The trip will review production quality, oversee downstream reeled-silk processing, and coordinate expansion with Prodigy Silk and the production network.
The company reiterated its near-term roadmap to scale toward a 10 metric ton monthly production target and highlighted leadership coverage in National Geographic.
Kraig Biocraft Laboratories (OTCQB: KBLB) reported deploying 700,000 BAM-1 Alpha production hybrids and producing >1.3 metric tons of recombinant spider silk cocoons in a single month (April 2026), a fivefold record increase. Management targets a near-term goal of 10 metric tons per month, moving from research to industrial-scale production.
The milestone validates the company’s vertically integrated platform—from genetic design to cocoon production—and signals potential commercial applications across textiles, aerospace, medical devices, and sustainable materials, while noting scaling, infrastructure, and demand-development challenges.
Kraig Biocraft Laboratories (OTCQB: KBLB) produced over 1.3 metric tons of recombinant spider silk cocoons in a single month on April 6, 2026, a fivefold increase over its prior record. The company says this validates its scale-up strategy and advances its plan to reach 10 metric tons per month within coming months.
Expanded facilities, new BAM-1 Alpha production hybrids, and vertically integrated operations reportedly enabled the ramp without operational disruptions.
Kraig Biocraft Laboratories (OTCQB: KBLB) is scaling its transgenic silkworm platform toward apparel-first commercialization by deploying ~1,000,000 proprietary spider-silk silkworm eggs and ramping three Vietnam facilities.
The company targets up to 10 metric tons of recombinant spider-silk cocoons per month and reports fibers with tensile strength up to 1.79 GPa.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced the deployment of more than 700,000 BAM-1 Alpha production hybrids from a previously reported 1,000,000 egg inventory on March 30, 2026. The silkworms are now in active production as part of an aggressive, milestone-driven scale-up plan aimed at reaching metric ton output levels.
Management says the BAM-1 Alpha hybrids are exceeding internal expectations for robustness and productivity, and the Company reports this release as a key execution milestone toward industrial-scale recombinant spider silk production.
Kraig Biocraft Laboratories (OTCQB: KBLB) expanded its R&D capacity for Project Atlas on March 23, 2026, roughly tripling screening throughput and adding staff and advanced equipment.
The upgrades automate testing workflows, strengthen analytical assays, increase parallel transgenic line evaluation, and aim to shorten development timelines and accelerate selection of production candidates.
Kraig Biocraft Laboratories (OTCQB: KBLB) says it deployed one million genetically engineered silkworm eggs across Vietnam to scale production of recombinant spider-silk cocoons, with a stated potential output near 10 metric tons per month. The company reported pilot shipments to several unannounced global brands and laboratory samples with tensile strengths near 1.8 GPa and elasticity above 38%.
The program combines traditional sericulture with transgenic silkworms and explores replacing native silk genes with spider sequences for purer spider silk.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced that Project Atlas, its next-generation bioengineering program, has passed a critical milestone and is advancing to the next phase. The program produced multiple new transgenic lines and aims to create novel spider-silk-based materials for industrial and defense uses.
The company noted Project Atlas merges multiple genetic elements into an integrated architecture to deliver enhanced strength, toughness, and other performance properties.